Cozaar Comp.

There is no image.

Method of action: Agents Acting In The Renin-Angiotensin System, Antihypertensive, Blocking At1-Receptors Of Angiotensin Ii, Diuretic, Hypotensive

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cozaar Comp.

Property	Description
Active ingredient	Losartan potassium, Hydrochlorothiazide (HCTZ)
Form	Oral film-coated tablet
Pharmacological class	Antihypertensive Combination Drug (ARB + Thiazide Diuretic)
General purpose	Sustained blood pressure reduction
Origin	Synthetic compound

What Type of Medicine is Cozaar Comp.?

Cozaar Comp. is a prescription-only, fixed-dose combination (FDC) preparation classified as an antihypertensive combination drug used for systemic administration. This pharmaceutical preparation belongs to the broader therapeutic class of cardiovascular medicines because its primary function is to manage blood pressure. Both of its active components are synthetic compounds designed to interact specifically with the body’s systems that regulate blood pressure. Being an FDC product, it simplifies the therapeutic approach by consolidating two distinct pharmacological actions into a single daily administration. The specific Losartan/HCTZ formulation is used for blood pressure management in adult patients when monotherapy is insufficient.

Composition: A Dual-Action Formulation

The active ingredients in Cozaar Comp. are Losartan potassium and Hydrochlorothiazide (HCTZ), which are integrated into a single oral film-coated tablet. Losartan potassium functions as an Angiotensin II Receptor Antagonist (ARB), targeting the hormonal system that controls blood vessel narrowing. Conversely, Hydrochlorothiazide is a Thiazide diuretic, which helps the body reduce excess fluid and salt. The presence of these two chemically distinct agents defines the drug's nature as a dual-acting formulation.

Primary Purpose of the Combination Therapy

The main purpose of the combination therapy is to achieve a synergistic antihypertensive effect that is stronger and more consistent than using either ingredient alone. By combining the vessel-relaxing action of Losartan with the volume-reducing action of HCTZ, Cozaar Comp. addresses two major physiological pathways of high blood pressure simultaneously. The combination of ARBs and HCTZ is a strategy for managing hypertension. This strategy leads to effective blood pressure reduction and relieves overall strain on the cardiovascular system in a typical use scenario for those with persistent hypertension.

What side effects are possible with Cozaar Comp.?

Official Safety Profile and Adverse Reactions

The safety profile of Cozaar Comp. (Losartan/Hydrochlorothiazide) is characterized by a range of officially documented adverse reactions, which are classified by frequency based on clinical trials and post-marketing data. Regulatory documents typically group these effects by System-Organ Class and severity.

Frequency-Classified Adverse Reactions

Classification	Examples of Reactions (SOC)
Common	Dizziness, upper respiratory infection, headache, back pain, asthenia/fatigue (General, Nervous, Musculoskeletal)
Uncommon	Sleep disorders, rash, nausea, vomiting, abdominal pain, Hypokalemia (Psychiatric, Gastrointestinal, Metabolic)
Rare	Angioedema (severe swelling), anaphylactic reaction, hepatitis (Immune, Hepatic)

Serious Adverse Reactions and Safety Constraints

Regulatory agencies define specific serious risks and constraints for this combination medicine. The most critical safety restriction is Fetal Toxicity, which involves the potential for fetal harm or death when the medicine is used during the second and third trimesters of pregnancy. Consequently, the medicine is contraindicated in pregnancy.

Other serious reactions and constraints include rare but clinically important events such as Angioedema (swelling of the face, throat, and/or tongue) and Acute Angle-Closure Glaucoma (an idiosyncratic reaction associated with the hydrochlorothiazide component).

Furthermore, the medicine is contraindicated in patients with severe hepatic impairment and those with severe renal impairment or anuria. The labeling also notes that the risk of Non-melanoma Skin Cancer is associated with the long-term use of the hydrochlorothiazide component.

Overdose and Emergency Response

Overdose and when to seek help

Overdose with Cozaar Comp. (Losartan potassium / Hydrochlorothiazide) is primarily characterized by the officially documented effects of profound blood pressure reduction and fluid/electrolyte disturbance. The core clinical manifestation is expected to be symptomatic hypotension (decreased blood pressure), which may be accompanied by cardiac changes such as tachycardia (fast heart rate) or bradycardia (slow heart rate).

Overdose of the diuretic component, Hydrochlorothiazide, can lead to profound volume depletion and severe laboratory abnormalities, including marked hypokalemia (low potassium) and hyponatremia (low sodium). The most serious potential outcome of these combined effects is cardiovascular collapse.

When to Seek Immediate Medical Help

The regulatory guidance is clear: immediate medical attention must be sought for any suspected overdose or for the development of symptomatic hypotension. Individuals are instructed to contact a regional poison control centre for management guidance. The management of a Cozaar Comp. overdose is strictly symptomatic and supportive, as no specific antidote is known.

Official prescribing information notes that hemodialysis is not effective for removing Losartan or its active metabolite. Furthermore, patients with hepatic impairment or renal impairment face an increased risk of exposure and potential toxicity in an overdose scenario.

Therapeutic Uses of Cozaar Comp.

Primary Therapeutic Management

This medication is applied across domains where additional symptomatic support is needed in the management of certain conditions. The medicine is commonly used across conditions presenting with acute episodes or those marked by increased physiological stress. The use is particularly relevant in clinical settings that involve acute or unstable symptom patterns, and treatment may assist with maintaining functional stability.

“It provides support that helps ease the overall symptom burden when symptoms become more noticeable.”

Supporting Functional Stability

Cozaar Comp. helps address symptom clusters that may become intense or disruptive, often used during phases of increased distress or discomfort. The support provided helps ease the overall symptom burden and supports the patient during difficult episodes by easing distress by targeting symptoms that create noticeable physiological strain and interfere with daily comfort. This supportive role is considered relevant when supportive symptom management is appropriate and short-term symptomatic assistance is needed to achieve better stability.

Quick Fact: This treatment assists with maintaining functional stability during conditions involving episodic or fluctuating manifestations.

Eligibility and Restrictions for Use

Eligibility Scope

Cozaar Comp. is designated for use in adult patients whose blood pressure is not adequately managed by losartan or hydrochlorothiazide monotherapy. Older adults may use the medicine, as dosage adjustment is not usually necessary.

Populations for Whom Use is Contraindicated

Use is absolutely prohibited in several populations according to regulatory documents. This includes pregnant women due to the risk of fetal harm, and patients with anuria or severe hepatic impairment. Contraindications also apply to individuals with hypersensitivity to any component or to sulfonamide-derived drugs. The medicine must not be used in patients with severe renal impairment (Creatinine Clearance leq 30 mL/min), therapy-resistant hypokalaemia or hypercalcaemia, or in diabetic patients taking Aliskiren.

Age-Related Eligibility and Restrictions

The combination product is not recommended for children and adolescents under 18 because safety and effectiveness have not been established in this age group. The medicine is also not recommended for women who are breastfeeding. Additionally, treatment is conditional: pre-existing conditions like volume or salt depletion must be corrected prior to administration.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section describes officially documented interaction patterns for Losartan/Hydrochlorothiazide (Cozaar Comp.) as defined by regulatory authorities.

Contraindicated Combinations and Restrictions

Co-administration with Aliskiren is formally contraindicated in patients with diabetes mellitus or moderate-to-severe renal impairment due to the documented risk of severe hypotension and hyperkalemia. Use with other agents that block the Renin-Angiotensin System, such as ACE Inhibitors, is generally not recommended.

Pharmacokinetic and Exposure Interactions

Interactions involving the metabolism of Losartan include effects from CYP2C9 enzyme modulators. For example, Fluconazole is documented to increase Losartan plasma exposure while simultaneously decreasing the exposure of its active metabolite. Conversely, inducers like Rifampicin and Phenobarbital are noted to reduce Losartan's overall exposure. To maintain the effectiveness of the hydrochlorothiazide component, drugs like Cholestyramine and Colestipol resins require a mandatory dose separation of at least 4 hours before or 4 to 6 hours after the resin's administration.

Pharmacodynamic Interactions

Co-administering this medicine with agents that increase serum potassium, such as potassium-sparing diuretics or potassium supplements, is not recommended due to the additive risk of hyperkalemia. Combination with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), including COX-2 inhibitors, may officially reduce the blood pressure-lowering effect and increase the risk of renal function deterioration. Additionally, the regulatory label advises that alcohol may potentiate orthostatic hypotension, and Grapefruit Juice should be avoided.

Mechanism of Action

Targeted Blockade of Hormonal Signaling

Losartan exerts its action by selective antagonism of the Angiotensin II Type 1 ( AT1) receptor, the central molecular target in the Renin-Angiotensin System ( RAS) cascade. This AT1 blockade suppresses the hormone Angiotensin II's signals for vasoconstriction and aldosterone release. The sustained effect is supported by its active metabolite, EXP3174, leading to a relaxation of vascular smooth muscle and a subsequent reduction in Total Peripheral Resistance ( TPR).

Modulation of Renal Fluid and Electrolyte Transport

Hydrochlorothiazide operates independently within the kidney by inhibiting the Sodium Chloride ( NaCl) symporter in the distal convoluted tubule. This mechanism blocks the reabsorption of Na^+ and Cl^- into the bloodstream, increasing their excretion alongside water (diuresis). This modulation of the renal pathway results in a predictable decrease in extracellular fluid volume, thereby lowering the volume load on the cardiovascular system.

Mechanism Synergy and Compensatory Neutralization

The combination therapy is fundamentally synergistic: Losartan prevents the Ang-II surge that is physiologically triggered by HCTZ's volume depletion, thereby preventing hormonal counter-regulation. Losartan’s secondary mechanism involves inhibition of the URAT1 transporter, which results in increased uric acid excretion, offsetting the effect of HCTZ on uric acid reabsorption.

Dosage and Administration Information

How Cozaar Comp. is used

Cozaar Comp. is an oral fixed-dose combination product administered as a film-coated tablet that must be swallowed whole with water. Administration is based on a once-daily schedule and may be taken with or without food.

Dosing and Administration Protocol

The combination product is generally not administered as initial therapy for essential hypertension. Its use is reserved for patients whose blood pressure is not adequately managed by monotherapy with either losartan or hydrochlorothiazide alone. The usual maintenance dose for adults is the 50 mg Losartan / 12.5 mg HCTZ tablet taken once daily.

For patients requiring further blood pressure control, the dosage may be adjusted up to the maximum approved dose of the 100 mg Losartan / 25 mg HCTZ tablet once daily. The maximal effect of the combination is typically achieved within three to four weeks of therapy initiation.

Procedural and Population Constraints

Prior to administration, volume or salt depletion must be corrected, as this is a mandatory pre-administration condition. For special populations, no initial dose adjustment is usually required for older adults. The product is not administered to pediatric patients (under 18 years) as safety and efficacy have not been established. If a scheduled dose is missed, it is typically recommended to take it as soon as it is remembered, unless it is nearly time for the next dose, in which case the missed dose is skipped; doses are not doubled.

Recent Clinical Evidence

Research evidence / Overview of studies for Cozaar Comp.

Evidence for Use in Essential High Blood Pressure

Cozaar Comp. was studied in research exploring high blood pressure through short-term Randomized Controlled Trials (RCTs) and various pooled analyses. This research primarily focused on adults diagnosed with high blood pressure, including those for whom specific blood pressure levels were not observed when using a single drug alone. Studies monitored patterns in blood pressure readings during combination use and compared these measurements to the data reported for the individual drug components used alone.

However, the existing evidence primarily focuses on short-term blood pressure measurements over periods typically lasting only a few weeks (4 to 12 weeks). There is limited information for long-term outcomes regarding the fixed-dose combination, as long-term data characterizing its effect on major cardiovascular health outcomes over many years are not widely available in dedicated FDC trials.

Evidence for Use in Cardiovascular Risk Management

Research has also examined the Losartan-based regimen in the context of long-term health, particularly for cardiovascular risk management. This evidence was observed in a large, international, long-term active-comparator Randomized Controlled Trial (known as the LIFE study). The study population consisted of older adults (aged 55 and above) who had high blood pressure and confirmed Left Ventricular Hypertrophy (LVH), a thickening of the heart muscle.

Researchers monitored a composite endpoint of major cardiovascular events, including cardiovascular death, heart attack, and the separate incidence of fatal and nonfatal stroke. The long-term trial reported patterns related to the measurement of stroke incidence in the two observed treatment regimens in the LVH population.

Certainty remains low when applying these findings broadly, as the key trial utilized an active comparator (an Atenolol-based regimen), which limits direct comparison to a placebo or other contemporary drug classes. Study reports indicated that the observed pattern related to stroke occurrence was not seen in the subgroup of Black patients included in the trial. Therefore, certainty remains low for outcomes in certain subgroups.

Frequently Asked Questions (FAQ)

Common questions about Cozaar Comp. (FAQ)

Q: How long does it take for this medication to start working, and how long does the effect last?

According to official product information, the losartan component is generally well-absorbed, with peak levels of the active substance reached in about one hour. The blood pressure-lowering effect is observed to be maintained for approximately 24 hours, which is consistent with once-daily administration. The active substance's effect is supported by a metabolite that remains in the body for up to nine hours.

Q: Is Losartan/HCTZ safe to take long-term?

The use of this medication is common for the sustained management of high blood pressure. While combination drug studies may focus on short-term blood pressure goals, clinical studies examining the losartan component show the blood pressure-lowering effect appeared to be maintained for up to a year during follow-up.

Q: Can this medication be used for anything other than high blood pressure?

Official regulatory documents state that this combination medication is indicated for lowering high blood pressure (hypertension). Additionally, it is indicated to help reduce the risk of stroke in patients who have hypertension along with a specific condition called left ventricular hypertrophy (enlargement of the heart muscle).

Q: Can this drug affect my blood sugar (glucose) levels?

Official warnings note that the hydrochlorothiazide component, the diuretic, may affect how your body handles sugar. This is known as impaired glucose tolerance. For patients who are taking antidiabetic medication, this effect may require adjustments to the diabetic treatment plan as determined by a healthcare provider.

Q: Can Losartan/HCTZ cause problems with sexual function?

Adverse reactions related to sexual function have been reported in postmarketing experience for losartan, one of the active ingredients. These reports include issues such as impotence and a reduction in sexual desire or performance. If concerns about sexual function arise, official guidance suggests consulting a healthcare provider for review.

Q: Do I need any special tests while taking this medication?

Regulatory guidance suggests that monitoring of certain blood levels may be needed for some patients. Monitoring of certain parameters, such as kidney function and serum potassium levels, is described in official documents for susceptible patients. If lithium is also being taken, blood lithium levels should be monitored.

Q: Does this drug have a Black Box Warning?

Yes, this medication carries a Boxed Warning from regulatory agencies regarding Fetal Toxicity. This is the most critical safety restriction because drugs that act on the renin-angiotensin system can cause injury and death to a developing fetus. The official guidance specifies that the medication should be discontinued as soon as pregnancy is detected.

Q: What happens if I take too much of this medication?

If too much of this medication is taken, the most likely effects are related to blood pressure. Regulatory documents state the primary symptoms are typically very low blood pressure (hypotension) and a rapid heartbeat (tachycardia). Excessive loss of body fluid (volume depletion) from the diuretic component is also a possible feature of an overdose.

Q: Does this drug cause a cough like some other blood pressure medicines?

The official safety profile indicates that cases of cough have been reported, primarily in postmarketing experience with losartan. However, studies show that the occurrence of cough with losartan is similar to that observed in patients taking hydrochlorothiazide or a placebo.

How should Cozaar Comp. be stored and disposed of?

How to Store and Dispose of Cozaar Comp.?

Official regulatory information provides specific instructions for the storage and final disposal of this medication to maintain its stability and ensure environmental safety.

Storage Requirements

Condition	Requirement
Temperature	Do not store above 30°C.
Protection	Keep in the original package/outer carton to protect from light and moisture. If in a bottle, keep tightly closed.
Safety	Keep all medicine out of the sight and reach of children. Use safety caps where applicable.
Expiration	Do not use the medicine after the expiry date printed on the packaging.

Disposal Instructions

Medicines should not be disposed of via household waste or wastewater (e.g., flushing down drains or toilets). To properly dispose of medication no longer needed, consult a pharmacist. Returning unused medicine to a pharmacist ensures that it is discarded in a manner that helps protect the environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.